Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 10;8(3):e58.
doi: 10.1002/hem3.58. eCollection 2024 Mar.

Clonal hematopoiesis and COVID-19 hospitalization in Danish adults

Celia Burgos Sequeros  1 , Morten Tulstrup  2   3 , Sofie Bliddal  4 , Karina Meden Sørensen  5 , Ioanna Nissen  6 , Omid Rezahosseini  7 , Patrick Terrence Brooks  6 , Bjarke Feenstra  6   8 , Anne Ortved Gang  2   9 , Frank Geller  6   8 , Annemette Hald  10 , Zitta Barrella Harboe  7   9 , Marie Helleberg  10   11 , Jakob S Jespersen  3   12 , Anne-Mette Lebech  9   10 , Birgitte Lindegaard  7   9 , Trine H Mogensen  13   14 , Maria Elizabeth Engel Møller  6 , Claus Henrik Nielsen  15 , Carsten Utoft Niemann  2   9 , Daria Podlekareva  16 , Adin Sejdic  7 , Erik Sørensen  6 , Rebecca Svanberg Teglgaard  2   6 , Niels Tommerup  17 , Nina Weis  9   18 , Søren Brunak  1 , Ole Birger Vestager Pedersen  9   19 , Karina Banasik  1   20 , Ulla Feldt-Rasmussen  4   9 , Susanne Dam Nielsen  9   10 , Sisse Rye Ostrowski  6   9 , Kirsten Grønbæk  2   3   9
Affiliations

Clonal hematopoiesis and COVID-19 hospitalization in Danish adults

Celia Burgos Sequeros et al. Hemasphere. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Kirsten Grønbæk has received research funding and/or consultancy fees from Janssen Pharma and GSK. Carsten Utoft Niemann has received research funding and/or consultancy fees from Abbvie, AstraZeneca, Janssen, Octapharma, Beigene, Genmab, CSL Behring, Takeda, Lilly, and MSD. Anne‐Mette Lebech has received unrestricted research grant from Gilead and consultancy fees from GSK, MSD, and Pfizer.

Figures

Figure 1
Figure 1
Clonal hematopoiesis of indeterminate potential (CHIP) and coronavirus disease 2019 (COVID‐19) hospitalization. (A) Characteristics of the matched case–control severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2)‐positive study participants. Cases and controls were matched by sex, age at the time of the SARS‐CoV‐2 polymerase chain reaction (PCR) test, and blood sample age. Blood sample age was calculated as the number of months between the blood sample collection and the PCR test. Negative values indicate that the blood sample was taken before the PCR test, and vice versa. (B) Oncoplot of co‐mutation patterns and bar plot of mutation prevalence in each CHIP gene. Only genes with a mutation prevalence ≥0.5% are shown. Mutations in the oncoplot are colored by variant type, as displayed in the legend. COVID‐19 hospitalizations and nonhospitalizations are represented in dark and light gray, respectively. (C) Associations between CHIP and COVID‐19 hospitalizations. CHIP status was evaluated based on the presence of: (1) any CHIP versus no CHIP, (2) multiple mutations versus no CHIP or a single mutation, (3) large (variant allele frequency [VAF] ≥ 10%) clone(s) versus no CHIP or small (VAF < 10%) clones, (4) mutation(s) in a DNA repair gene (PPM1D and/or TP53) versus no CHIP or mutation(s) elsewhere, and (5) mutation(s) in PPM1D versus no CHIP or mutation(s) elsewhere. In gray, the results of the univariable analysis are shown; in black, those of the multivariable analysis adjusted for blood sample age, body mass index, active smoking, diabetes, cardiovascular disease, lung disease, cancer, and prior chemo‐ and/or radiotherapy treatment. BMI, body mass index; CI, confidence interval; ICU, intensive care unit; OR, odds ratio.
Figure 2
Figure 2
Clonal hematopoiesis of indeterminate potential (CHIP) and intensive care unit (ICU) admission or in‐hospital death, in coronavirus disease 2019 (COVID‐19) hospitalized study participants. (A) Characteristics of the COVID‐19 hospitalized study participants, by type of admission. Blood sample age was calculated as the number of months between the blood sample collection and the polymerase chain reaction (PCR) test. Negative values indicate that the blood sample was taken before the PCR test, and vice versa. (B) Oncoplot of co‐mutation patterns and bar plot of mutation prevalence in each CHIP gene. Only genes with a mutation prevalence ≥0.5% are shown. Mutations in the oncoplot are colored by variant type, as displayed in the legend. ICU admissions/in‐hospital deaths and general admissions are represented in dark and light gray, respectively. (C) Associations between CHIP and ICU admissions/in‐hospital deaths. CHIP status was evaluated based on the presence of: (1) any CHIP versus no CHIP, (2) multiple mutations versus no CHIP or a single mutation, (3) large (variant allele frequency [VAF] ≥ 10%) clone(s) versus no CHIP or small (VAF < 10%) clones, (4) mutation(s) in a DNA repair gene (PPM1D and/or TP53) versus no CHIP or mutation(s) elsewhere, and (5) mutation(s) in PPM1D versus no CHIP or mutation(s) elsewhere. In gray, the results of the univariable analysis are shown; in black, those of the multivariable analysis adjusted for sex, age at the time of the positive severe acute respiratory syndrome coronavirus 2 PCR test, blood sample age, body mass index, active smoking, diabetes, cardiovascular disease, lung disease, cancer, and prior chemo‐ and/or radiotherapy treatment. BMI, body mass index; CI, confidence interval; OR, odds ratio.
See this image and copyright information in PMC

References

    1. Jaiswal S, Fontanillas P, Flannick J, et al. Age‐related clonal hematopoiesis associated with adverse outcomes. N Engl J Med. 2014;371(26):2488‐2498. 10.1056/NEJMoa1408617 - DOI - PMC - PubMed
    1. Joo L, Bradley CC, Lin SH, Scheet PA, Nead KT. Causes of clonal hematopoiesis: a review. Curr Oncol Rep. 2023;25(3):211‐220. 10.1007/s11912-023-01362-z - DOI - PMC - PubMed
    1. Zekavat SM, Lin SH, Bick AG, et al. Hematopoietic mosaic chromosomal alterations increase the risk for diverse types of infection. Nat Med. 2021;27(6):1012‐1024. 10.1038/s41591-021-01371-0 - DOI - PMC - PubMed
    1. Li X, Zhang Q, Ding Y, et al. Methyltransferase Dnmt3a upregulates HDAC9 to deacetylate the kinase TBK1 for activation of antiviral innate immunity. Nature Immunol. 2016;17(7):806‐815. 10.1038/ni.3464 - DOI - PubMed
    1. Zhang Q, Zhao K, Shen Q, et al. Tet2 is required to resolve inflammation by recruiting Hdac2 to specifically repress IL‐6. Nature. 2015;525(7569):389‐393. 10.1038/nature15252 - DOI - PMC - PubMed